Shares of Cipla plunged over 3% to ₹1,382.3 in early trade on Friday after the pharma major disclosed that it is temporarily pausing the manufacturing of a key drug. The production of Lanreotide drug is expected to resume in the first half of FY27. Brokerage firms Morgan Stanley and Nuvama reduced their target prices for Cipla shares following the disclosure.